01—Abstract
Summary
Summary of the 8-K filed July 7, 2026. Cited figures are marked; the original filing is the authoritative source.
ResMed Inc. (NYSE: RMD) reported in an Item 2.02 Form 8-K filed July 7, 2026 that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on healthcare, for $490 milliona in cash, subject to certain closing adjustments.
The transaction is expected to close during the first quarter of fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Resmed intends to use the net proceeds to return capital to shareholders, including through an accelerated share repurchase (ASR) program, and for general corporate purposes. According to the filing, MatrixCare represented approximately $220 millionb of revenue and approximately $55 million of non-GAAP operating profit based on preliminary full fiscal year 2026 results.
Resmed expects transition services agreements to largely offset first-year post-closing stranded costs and intends to mitigate remaining stranded costs over time. The company also said its recently completed Noctrix acquisition is expected to contribute approximately $30 millionc of revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal year 2027. Resmed continues to expect its Residential Care Software (RCS) segment to accelerate to high single digit percentage year-over-year revenue growth, along with operating leverage, in fiscal 2027.
It reiterated its fiscal 2026 outlook for non-GAAP gross margin, non-GAAP SG&A and R&D as a percentage of revenue, and non-GAAP tax rate, along with its fourth-quarter fiscal 2026 outlook for net interest income and planned share repurchases. Full fiscal 2027 guidance will be provided on the fourth-quarter fiscal 2026 earnings call on August 6, 2026.
02—Key points
Key Highlights
- Agreement to sell MatrixCare business to Frazier Healthcare Partners for $490 million all-cash, subject to certain closing adjustments
- Expected closing in the first quarter of fiscal year 2027, subject to regulatory approvals and customary closing conditions
- MatrixCare represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit in preliminary fiscal 2026 results
- Net proceeds intended for shareholder returns, including an accelerated share repurchase (ASR) program, and general corporate purposes
- Transition services agreements expected to largely offset first-year post-closing stranded costs
- Noctrix acquisition expected to contribute approximately $30 million of revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal 2027
- Full fiscal 2027 outlook to be provided on the August 6, 2026 fourth-quarter fiscal 2026 earnings call; fiscal 2026 outlook items reiterated
03—Questions
Frequently Asked Questions
What is being sold and to whom?
Resmed agreed to sell its MatrixCare business to Frazier Healthcare Partners. The press release states the transaction includes MatrixCare and related offerings such as Healthcare First, Citus, and home health and hospice solutions, and excludes Brightree in the U.S. and MEDIFOX DAN in Germany.
How much is the transaction worth and what will the proceeds be used for?
The transaction is a $490 million all-cash deal, subject to certain closing adjustments. Resmed intends to use net proceeds to return capital to shareholders, including through an accelerated share repurchase program, and for general corporate purposes.
When is the deal expected to close?
The transaction is expected to close during the first quarter of Resmed's fiscal year 2027, subject to required regulatory approvals and customary closing conditions.
How will the divestiture affect Resmed's financials?
The filing states MatrixCare represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit in preliminary fiscal 2026 results. Transition services agreements are expected to largely offset stranded costs in the first year after closing, and Resmed intends to mitigate remaining stranded costs over time. Further financial impact details will be provided in fourth-quarter fiscal 2026 regulatory filings.
What guidance did Resmed provide?
Resmed expects its Residential Care Software segment to accelerate to high single digit percentage year-over-year revenue growth with operating leverage in fiscal 2027. It reiterated its fiscal 2026 outlook for non-GAAP gross margin, non-GAAP SG&A and R&D as a percentage of revenue, and non-GAAP tax rate, plus its fourth-quarter fiscal 2026 outlook for net interest income and planned share repurchases. Full fiscal 2027 outlook will come on the August 6, 2026 earnings call.
04—Continue